Review on clinical research progress of immunotherapy in liver cancer
10.16438/j.0513-4870.2019-0585
- VernacularTitle:免疫治疗联合靶向治疗在晚期肝癌方面的临床研究进展
- Author:
Shi-jia YAN
1
;
Xian-ya LIU
1
;
Guo-hui WAN
1
Author Information
1. School of Pharmaceutical Sciences, Sun Yat-san University, Guangzhou 510006, China
- Publication Type:Research Article
- Keywords:
liver cancer;
immunotherapy;
immune checkpoint inhibitor;
tyrosine kinase inhibitor;
rug combination
- From:
Acta Pharmaceutica Sinica
2019;54(10):1749-1754
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, which is characterized by complex pathogenesis, inconspicuous early symptoms, rapid progress and poor prognosis. Immunotherapy and targeted therapy are important methods to treat advanced and metastatic liver cancer in recent years. With the FDA's approval of sorafenib and other tyrosine kinase inhibitors and programmed cell death protein 1 and cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors for the treatment of liver cancer, great progress has been made in single-agent therapy and combination therapy, bringing a new turning point for the improvement of survival rate of patients with advanced liver cancer. However, the mechanism of immunotherapy and drug resistance is still unclear, and its clinical application combined with targeted and other therapies is still under research, which needs to be further explored by researchers. In this paper, the clinical research progress of immunotherapy combined with other therapies in advanced hepatocellular carcinoma was reviewed, in order to grasp the current development trend of the treatment of hepatocellular carcinoma and provide reference for the further development direction of immunotherapy.
